GILEAD SCIENCES
18 patent applications for HIV drug lenacapavir may delay affordable generics in India
Gilead Sciences has filed 18 patent applications in India for lenacapavir, raising concerns among patient groups. They argue these applications may hinder the availability of affordable generic versions of the HIV drug. Consumer advocates have approached the patent office, seeking a rejection of these filings as they may constitute evergreening. If granted, these patents could remain valid until 2042, extending exclusive rights.
Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally
Dr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America weakness pressured performance, offset partly by growth in India and emerging markets, alongside biosimilar approvals and strategic partnerships.
Dr Reddy's inks pact with Gilead for once-yearly HIV prevention drug lenacapavir
Dr Reddy's Laboratories and Gilead Sciences have signed a licensing agreement. This pact involves investigational once-yearly lenacapavir for HIV prevention. The agreement facilitates manufacturing and supply planning for 120 countries. This collaboration builds upon a previous pact for twice-yearly lenacapavir.
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?of Gilead Sciences, was partnering with Arcellx ?to jointly develop and sell anito-cel, an experimental CAR-T therapy for multiple myeloma, a type of blood cancer.
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details here
US Stock Market indexes S&P 500, Nasdaq, and Dow Jones made weekly gains as Gilead Sciences Inc (GILD) and Expedia Group Inc (EXPE) stocks are rising.
Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir
Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries, especially resource-limited nations. Emcure aims to provide high-quality, low-cost HIV medication to improve health outcomes globally.
- Go To Page 1

Dr Reddy’s inks licensing pact with Gilead for Remdesivir to treat Covid-19
The Hyderabad headquartered drug maker will obtain technology transfer from Gilead for manufacturing of the drug wherein the Indian firm would need to do the manufacturing scale up.

BDR in pact to make Gilead drug for Cipla
In late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead. The Mumbai-based company has now signed a contract to make the drug for Cipla, which is one of the licensed companies.

US pharma firm Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India
Officials of the Union Health Ministry, along with the Drugs Controller General of India (DCGI) held a discussion with the representatives of Gilead Sciences on Wednesday to prepare a road map for introducing remdesivir in India, sources said.

More companies in talks for Remdesivir licence
This week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received emergency use authorisation from the US Food and Drug Administration after trial results showed that it halved the recovery time to five days for moderately affected patients.

Gilead sign licensing deal for Remdesivir with three Indian companies
ET had reported on May 5 that Gilead Sciences was in talks with several Indian companies including Jubilant Life Sciences for a licensing deal.

Gilead under gun to mass-produce virus drug or risk exclusivity
All of that could add up to market wins if remdesivir lives up to expectations and Gilead can ramp up to sufficiently respond to Covid-driven demand. But if it can’t, Gilead could be “very vulnerable” to the federal government using its powers to compel the licensure of remdesivir patents, Roth said.

Gilead's antiviral drug remdesivir flops in first trial
The Chinese trial showed the antiviral remdesivir did not improve patients' condition or reduce the pathogen's presence in the bloodstream, the report said.

NPPA seeks clarification on Gilead's drug pricing plea
National Pharmaceutical Pricing Authority has sought clarifications from the company. Gilead had sought exemption from price control for its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a major chunk of Rs 140-crore market for chronic Hepatitis B in India.

Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rights
Legal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata Patent Office.

Natco gets DCGI nod to launch hepatitis C drug in India
Natco Pharma has received approval from the Drugs Controller General of India (DCGI) to launch generic version of hepatitis C treatment drug in India.

Natco settles patent suit with Gilead, others over Tamiflu
Natco Pharma and its partner Alvogen today said they have settled patent infringement suit with Gilead Sciences Inc and others over Tamiflu.

Mylan launches hepatitis-C Sovaldi tablets in India
Sovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.

Dr Reddy's to launch Hepatitis C drug in India
Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Zydus Cadila launches Gilead's Hepatitis C drug in India
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Strides Arcolab inks pact with Gilead Sciences for HIV drug
Strides has entered into a licensing agreement with Gilead to manufacture and distribute latter's low-cost TAF used for HIV treatment in developing countries.

Shilpa Medicare inks pact with MPP, Gilead for HIV/AIDS drugs
Shilpa Medicare inked an agreement with Gilead Sciences to increase access to medicines used for treatment of HIV/AIDS.

CCI rules out case against Gilead Sciences
CCI has rejected a complaint against Gilead Sciences Inc that alleged the US-based pharmaceutical company of abusing its dominant position.
Strides signs pact with Gilead Sciences to promote HIV drug
Strides Arcolab said it has inked a pact with US-based Gilead Sciences to sell low-cost generic versions of latter's HIV medicine 'emtricitabine' in developing countries.
Strides Arcolab inks pact with Gilead Sciences to promote HIV drug
Strides has inked a pact with Gilead Sciences Inc to sell low-cost generic versions of latter's HIV medicine 'emtricitabine' in developing countries.
Gilead Sciences inks deals with 3 Indian companies including Ranbaxy Laboratories for low-cost HIV drug
Gilead Sciences has signed deals with 3 Indian firms to collaborate on promoting access to HIV medicine emtricitabine in developing nations.
US bio-pharma firm Gilead Sciences in pact with four Indian cos
US-based bio-pharmaceutical company Gilead Sciences on Tuesday entered into new licensing pacts with four Indian firms.
Ranbaxy inks pact with Gilead for three generic HIV/AIDS drugs
Ranbaxy has entered into an agreement with US-headquartered Gilead Sciences to manufacture and market three new generic HIV/AIDS drugs.
US' Gilead appeals against patent rejection of AIDS drug Viread
US drug company Gilead Sciences has filed an appeal in the Indian Intellectual Property Appellate Board (IPAB) to challenge a recent order by an Indian Patent Office that rejected two patent claims for its best seller drug Viread (tenofovir disoproxil fumarate).
Load More